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patients (+6.8 letters) compared with phakic patients (–2.5 
letters) 12 months after ILUVIEN ® . The mean central subfield 
thickness decrease from baseline to month 12 was statisti-
cally significant, with a rapid reduction in the first week. Re-
garding safety, only 2 patients showed an intraocular pres-
sure (IOP) increase over 25 mm Hg during the study, and the 
rise in IOP was well managed with eye drops only.  Conclu-
sions: This prospective and pilot study suggests that ILUVI-
EN ® is safe and may be considered effective for chronic DME 
patients insufficiently responsive to other available thera-
pies as it showed a rapid and sustained improvement of 
macular edema obtained after treatment with ILUVIEN ® . 
 © 2017 S. Karger AG, Basel 
 Introduction 
 Diabetes is expected to affect almost 642 million peo-
ple worldwide in 2040 and likely to lead to large increases 
in the rates of complications related to diabetes, including 
diabetic retinopathy (DR) and diabetic macular edema 
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 Abstract 
 Purpose: The aim of this study was to assess the effective-
ness and safety of ILUVIEN ® in patients with chronic diabet-
ic macular edema (DME) who were insufficiently responsive 
to prior therapies.  Methods: This is a prospective, nonran-
domized, multicenter, open-label, phase 4 pilot study as-
sessing the effectiveness and safety of ILUVIEN ® involving 
12 patients insufficiently responsive to available therapies. 
Assessments were performed at screening, baseline, week 1, 
and months 1, 3, 6, 9, and 12. Demographics, medical/oph-
thalmic history, prior laser, anti-VEGF, and steroid treat-
ments, and lab tests were recorded at screening. A complete 
ophthalmic examination and SD-OCT were performed at 
screening and at all follow-up visits.  Results: The patients 
showed improvements in best-corrected visual acuity (+3.7 
letters), with greater improvement among pseudophakic 
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(DME)  [1, 2] . Globally, nearly 93 million people current-
ly have DR, 17 million have proliferative DR, 21 million 
have DME, and 28 million are living with a vision-threat-
ening form of the disease  [3] .
 DME remains a major cause of vision loss in patients 
with diabetes. Its pathogenesis is complex and multifacto-
rial, largely caused by a change in the permeability across 
the blood-retinal barrier (BRB) as a result of hyperglyce-
mia  [4] . BRB breakdown allows the leakage of fluid and 
small and large molecules across the compromised BRB, 
causing macular edema  [5] .
 At early disease stages, vascular endothelial growth 
factor (VEGF) is primarily responsible for retinal chang-
es, owing to its overexpression. VEGF inhibitor therapies 
are currently used as treatment options in DME  [5, 6] . 
Within the past few years, VEGF inhibitors, such as ra-
nibizumab, aflibercept, and bevacizumab (used off-label) 
have been part of the therapeutic arsenal of ophthalmolo-
gists for treating DME. However, it is estimated that up 
to 40% of patients are insufficiently responsive to anti-
VEGF intravitreal therapy and other treatment options 
are necessary in these cases. It is well established that in-
flammation has an important role in the pathophysiology 
of DME, and intravitreal steroids, such as triamcinolone 
acetonide, and more recently intravitreal steroid drug de-
livery systems like fluocinolone acetonide (FAc; ILUVI-
EN ® , Alimera Sciences Inc., Atlanta, GA, USA) and dexa-
methasone (Ozurdex ® , Allergan Inc., Irvine, CA, USA) 
have been successfully used in the treatment of visual im-
pairment due to DME  [7, 8] .
 Recent studies focused on patients with chronic DME 
demonstrated that there are numerous inflammatory cas-
cades due to chronic microglia activation resulting from 
retinal damage that leads to cytokine production by reti-
nal cells in the eye  [6] . At this stage, VEGF is likely no 
longer primarily responsible for the biochemical and 
physiological changes in the eyes and anti-VEGF agents 
are consequently less effective. Due to their multifacto-
rial mode of action, steroids are probably most effective 
at this stage  [6] .
 Whilst an intravitreal bolus injection of a steroid into 
the eye provides a rapid (pulse) release of the active drug 
with a short-term pharmacological effect, repeated injec-
tions are necessary  [9, 10] . In contrast, a single injection 
of ILUVIEN ® provides a sustained, low-dose delivery of 
FAc for up to 36 months  [11, 12] , avoiding the need for 
frequent injections and requiring only routine assess-
ments (e.g., intraocular pressure, IOP, and cataract for-
mation)  [13] .
 This investigator-driven clinical trial is the first real-
life clinical experience with ILUVIEN ® in Portugal and 
will assess the effectiveness and safety of the ILUVIEN ® 
intravitreal implant in chronic DME patients considered 
insufficiently responsive to available therapies.
 Materials and Methods 
 Study Design 
 This is a prospective, nonrandomized, multicenter, open-label 
phase 4 pilot study. Twelve patients were enrolled at 4 Portuguese 
sites: 1 site with 4 patients, 2 sites with 3 patients, and 1 site with 2 
patients. Men and women aged  ≥ 18 years with chronic DME, de-
fined as persistent macular edema for more than 1 year in the study 
eye, considered insufficiently responsive to other previous treat-
ments, including at least 3 anti-VEGF injections in the last 6 
months, were included. Further inclusion requirements were: 
mean central foveal thickness at baseline (central subfield thick-
ness; CST)  ≥ 290 μm in women and  ≥ 305 μm in men with Zeiss 
Cirrus or  ≥ 305 μm in women and  ≥ 320 μm in men with Heidel-
berg Spectralis in the study eye, as measured using SD-OCT (spec-
tral domain optical coherence tomography); vision impairment 
(20/50 to 20/400 using Snellen visual acuity equivalent) related to 
DME, and the investigator’s opinion that a further visual improve-
ment is possible.
 Exclusion criteria in the study eye included: IOP >21 mm Hg 
at screening; history of a rise in IOP >25 mm Hg following treat-
ment with an intravitreal steroid; use of  ≥ 2 active agents as IOP-
lowering medications to control IOP at screening; previous vitreo-
macular traction in DME and opaque media; severe proliferative 
DR requiring pan retinal photocoagulation; diagnosis of angio-
graphic central macular ischemia; previous pan retinal photoco-
agulation or cataract surgery in the 3 months prior to the screening 
visit; contraindications according to the current Summary of 
Product Characteristics  [14] ; the presence of preexisting glauco-
ma; active or suspected ocular or periocular infection, and hyper-
sensitivity to the active agent or to 1 of the excipients  [14] . Preg-
nant or breastfeeding women and women of child-bearing poten-
tial not using a highly effective method of birth control were also 
excluded.
 This study was designed, implemented, and reported in accor-
dance with the ICH Harmonized Tripartite Guidelines for Good 
Clinical Practice, with applicable local regulations (including Eu-
ropean Directive 2001/20/EC) and with the ethical principles laid 
down in the Declaration of Helsinki.
 Eligible patients only participated in the study after providing 
approved written informed consent. The study was registered with 
EudraCT (No. 2014-003491-23) and it was conducted from Octo-
ber 2014 to July 2016.
 Study Treatment 
 The ILUVIEN ® implant is an injectable intraocular sustained-
release drug delivery system for FAc preloaded into a single use 
sterile applicator. Each implant contains 190 μg of FAc as the active 
ingredient within a 3.5-mm-long cylindrical polyimide tube with 
an internal diameter of 0.37 mm. The implant is to be injected 
through the pars plana into the vitreous using a 25-G needle.
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 All patients received the ILUVIEN ® 190-μg intravitreal im-
plant in an applicator (releasing 0.2 μg of FAc per day) at the inclu-
sion visit. The implant was administered by injection according to 
the method of administration defined in the summary of product 
characteristics  [14] . Only 1 eye of each patient was treated with 
ILUVIEN ® . In case of bilateral DME, the fellow eye received ocu-
lar treatments according to the standard clinical practice.
 Outcomes 
 The defined study outcomes were:
 • changes in best-corrected visual acuity (BCVA) from baseline 
to month 12; 
 • changes in central retinal thickness assessed using spectral do-
main optical coherence tomography (SD-OCT) from baseline 
to month 12; 
 • adverse events, namely cataract and elevated IOP. 
 Visits and Assessments 
 This 12-month study included 8 visits. After informed consent 
was obtained and, prior to enrolment, the patients were evaluated 
to determine eligibility. Patient assessments were performed at 
screening, baseline, week 1, and months 1, 3, 6, 9, and 12 to assess 
the effectiveness and safety of ILUVIEN ® . The following were re-
corded at the screening visit: demographics, diabetes history, diag-
nosis of DME, medical/ophthalmic history, prior laser, anti-VEGF, 
and steroids treatments, and lab tests. The following assessments 
were performed at the screening visit and at all follow-up visits: an 
ophthalmic examination consisting of BCVA (using Early Treat-
ment Diabetic Retinopathy Study, ETDRS, charts), IOP, CST, and 
macular volume (MV) using SD-OCT, corneal thickness (via spec-
tral SD-OCT), slit lamp examination, ophthalmoscopy, fundus 
photography, lens status, and DR severity. Concomitant medica-
tions, ocular procedures, and adverse events were recorded during 
the follow-up visits.
 Statistical Analysis 
 All of the effectiveness variables were analyzed using the intent-
to-treat data set for patients who had a valid baseline assessment. 
The variables for assessing effectiveness included BCVA in ETDRS 
letters and retinal thickness parameters assessed using SD-OCT 
(i.e., CST and MV). The observed change from baseline values for 
each variable were summarized descriptively (mean ± SD) or by 
the frequency distribution assessed at each visit.
 Safety analyses were performed by evaluating ocular adverse 
events, BCVA, IOP, hemoglobin A 1c , slit lamp exams, ophthal-
moscopy, and concomitant ocular medications and therapies. Sys-
temic safety was assessed by evaluating nonocular adverse events, 
and concomitant nonocular medications and therapies. The non-
parametric Wilcoxon signed-rank test was used to assess differ-
ences between screening and month 12, and the nonparametric 
Wilcoxon-Mann-Whitney test was used to assess differences be-
tween phakic and pseudophakic patients. For continuous vari-
ables, such as IOP, the observed and change from baseline values 
were summarized descriptively (mean ± SD) at each visit. Categor-
ical variables were summarized by counts and percentages. A  p 
value <0.05 was considered to be statistically significant. Statistical 
analyses were performed on Stata version 12.1 (StataCorp LP, Col-
lege Station, TX, USA).
 Results 
 Demographic Characteristics of Study Population 
 The demographics of 8 male and 4 female patients and 
baseline characteristics of the study eyes ( n = 12) are de-
scribed in  Table 1 . The mean age of the patients was 69.6 
± 9.3 years. Eight eyes were pseudophakic and 4 were pha-
kic. At inclusion, the eyes had a mean DME duration of 
3.4 ± 3.1 years, the mean BCVA was 48.8 ± 10.9 letters, 
and the CST was 650.5 ± 140.9 μm. 
 All of the patients had prior anti-VEGF with a mean 
number of 4 injections and 75% of them had associated 
 Table 1.  Demographics and baseline characteristics of the study 
patients and eyes
Characteristics
Patients 12
Gender
Male 8 (66.7)
Female 4 (33.3) 
DR severity
None 3 (25.0)
Moderate 2 (16.7)
Severe 1 (8.3)
Proliferative 1 (8.3)
Laser 5 (41.7)
Age, years 69.6 ± 9.3
Lens status
Pseudophakic 8 (66.7) 
Phakic 4 (33.3) 
Diabetes
Type 1 0 (0)
Type 2 12 (100)
Diabetes duration, years 19.1 ± 11.1
DME duration, years 3.4 ± 3.1
HbA1C, % 6.9 ± 1.3
SBP, mm Hg 153.0 ± 21.6
DBP, mm Hg 77.1 ± 8.7
IOP, mm Hg 14.6 ± 2.9
BCVA, ETDRS letters 48.8 ± 10.9
CST, μm 650.5 ± 140.9
MV, mm3 11.6 ± 2.0
Previous treatments
Laser + anti-VEGF + steroids 4 (33.3)
Laser + anti-VEGF 5 (41.7)
Anti-VEGF alone 3 (25.0)
Laser alone 0 (0.0)
Number of previous treatments
Previous laser sessions 4.4 ± 4.2
Previous anti-VEGF injections 4.0 ± 2.9
Previous steroids treatments 2.0 ± 1.4
Data are presented as n (%) or mean ± SD.
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therapies (laser or steroids). Details for the previous treat-
ments and the number of previous treatments are includ-
ed in  Table 1 .
 Visual Outcomes: BCVA 
 This study showed that a single injection of ILUVI-
EN ® led to a BCVA improvement in 9 of the 12 patients 
with chronic DME who were considered insufficiently re-
sponsive to first-line therapies. Although the average 
BCVA difference from baseline to month 12 (+3.7 letters; 
 Fig. 1 ) was not statistically significant ( p = 0.255), there 
was an almost statistically significant trend for improve-
ment among pseudophakic patients (mean difference 
+6.8 letters,  p = 0.058), which was not present in phakic 
eyes (mean difference –2.5 letters,  p = 0.715;  Fig. 2 ). Pseu-
dophakic eyes showed a BCVA improvement from base-
line that reached statistical significance between week 1 
and month 6 (week 1,  p = 0.019; month 1,  p = 0.014; 
month 3,  p = 0.025; month 6,  p = 0.012), while phakic eyes 
had a quick gain of 5 letters in the first week followed by 
a decrease of visual acuity that did not reach statistical 
significance ( Fig. 2 ).
 Anatomical Outcomes: CST and MV 
 Statistically significant improvements in the average 
CST (–292.83 μm,  p = 0.003) and average MV (–1.8 mm 3 , 
 p = 0.005) were observed in 92% of the patients from base-
line to month 12. There was a significant and rapid de-
crease of macular edema in the first week after ILUVI-
EN ® implant insertion, with a mean CST change of 
 − 203.3 μm, which was sustained over the 12-month fol-
low-up ( Fig. 3 ).
 Safety 
 Regarding safety, no surgeries or trabeculectomies 
were needed to control IOP. Nevertheless, statistically 
significant differences were observed from baseline to 
month 12 for IOP ( p = 0.005). However, only 5 patients 
experienced an IOP over 22 mm Hg during the study, 2 
of which had an IOP over 25 mm Hg, and no subjects had 
an IOP over 30 mm Hg ( Fig. 4 ). Of the 5 patients with an 
elevated IOP, 4 (80%) were phakic. These patients were 
all well controlled with eye drops. One of the patients had 
a worsening of preexisting cataract and underwent sur-
gery, showing an improvement of the edema and visual 
acuity.
 No patients were discontinued from the study. No se-
rious adverse events relating to the study drug were re-
ported. Regarding glycemic control, no statistically sig-
nificant differences were found in hemoglobin A 1c levels 
from baseline to month 12 ( p = 0.623).
 Discussion 
 The purpose of this study was to monitor safety and 
effectiveness in real-life chronic DME patients consid-
ered insufficiently responsive to available therapies. The 
study population included patients with a mean DME du-
ration of 3.4 years who had undergone at least 3 anti-
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VEGF injections in the last 6 months. Prior to treatment 
with ILUVIEN ® , 4 patients/eyes had been previously 
treated with laser, anti-VEGF, and steroids, 5 patients had 
been previously treated with laser and anti-VEGF, and 3 
patients had been previously treated with only anti-
VEGF. Indeed, patients initially treated with anti-VEGF 
and/or steroids had not been assessed in the Fluocinolone 
Acetonide for Macular Edema (FAME) studies (phase III 
trials of the efficacy and safety of ILUVIEN ® in DME pa-
tients)  [13] . In comparison with the FAME studies, the 
patients included in this study had worse baseline char-
acteristics, including diabetes duration, baseline BCVA, 
and baseline CST.
 In our study, 9 eyes had DR reported at baseline with 
different grades of severity. Recent data show that ILU-
VIEN ® slows the development of both proliferative and 
nonproliferative DR  [15] .
 At baseline, the mean BCVA was 48.8 ± 10.9 letters, 
demonstrating significant vision impairment related to 
DME. Ten patients maintained or improved their BCVA 
scores from baseline to month 12. The mean improve-
ment of BCVA letter score was +3.7 at 12 months. This 
modest mean improvement of BCVA may be attributed 
to the development and/or worsening of cataract ob-
served from month 6, where the mean BCVA gain was 
+6.8. Although the average BCVA difference from base-
line to month 12 was not statistically significant, there was 
an almost statistically significant trend for improvement 
among pseudophakic patients (mean difference +6.8 let-
ters,  p = 0.058), which was not present in phakic eyes 
(mean difference –2.5 letters,  p = 0.715). Pseudophakic 
eyes showed a BCVA improvement that reached statisti-
cal significance between week 1 and month 6, while pha-
kic eyes had a quick gain of 5 letters in the first week fol-
lowed by a progressive decrease of visual acuity, probably 
due to cataract progression, which did not reach statisti-
cal significance. In FAME, the median time for cataract 
to be reported as an adverse event was 12 months and the 
median time for cataract surgery was 18 months  [13] . An-
other possible cause for poor visual acuity improvement 
was the microstructural and nonreversible lesions in ret-
inal layers after chronic and long-standing edema in the 
patients enrolled  [16] . This would suggest the benefit of 
an early use of ILUVIEN ® , as has already been described 
 [17] .
 In the subgroup analysis, pseudophakic patients had a 
higher mean letter gain of +6.8 letters than the phakic pa-
tients at 12 months. Cataract development and/or wors-
ening occurred at the expected rate in phakic patients 
treated with ILUVIEN ® , as this is a known effect of intra-
vitreal steroid therapies  [18] . The only case of cataract 
extraction performed in our study showed improvement 
of the macular edema and visual acuity. In fact, it has been 
discussed that a low dose of a steroid, such as ILUVIEN ® , 
is beneficial during and after cataract surgery in eyes with 
DME due to its protective effect  [18] . Results from a phase 
4 study with ILUVIEN ® in DME reported by Massin et 
al.  [17] showed a benefit in BCVA and anatomical im-
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provements, which were consistent with our study. The 
mean improvement of BCVA letter score (excluding val-
ues postrescue) at 1 year was +4.9 in patients who had 
received previous treatment in the study eye with laser 
photocoagulation for DME and no previous treatment 
with intraocular anti-VEGF therapy, and +4.4 in patients 
previously treated in the study eye with laser photocoagu-
lation for DME (including focal/grid and pan-retinal) 
and with a past history of  ≥ 3 monthly anti-VEGF treat-
ments. This last parameter was +8.2 in pseudophakic pa-
tients.
 At baseline, the mean CST and MV in our patient pop-
ulation were 650.5 ± 140.9 μm and 11.6 ± 2.0 mm 3 , re-
spectively, confirming the insufficient DME response to 
prior therapies. In our study, there was a rapid reduction 
in mean CST, which was significant as early as week 1 
with a gradual and sustained reduction over the 12-month 
follow-up period. The mean decrease of CST and MV was 
–292.83 μm and –1.8 mm 3 respectively, at month 12, both 
of which were statistically significant. Given the antici-
pated poor potential for visual acuity gain due to chronic 
retinal lesions, the reduction in CST should be considered 
the best indicator of the efficacy of the treatment. There-
fore, even in chronic and long-standing edema the ana-
tomic results are very good evidence of the efficacy of 
long-acting steroids like ILUVIEN ® . In the study by Mas-
sin et al.  [17] , at month 1 the mean decrease of CST was 
–239 μm in the group of patients that had received previ-
ous treatment in the study eye with laser photocoagula-
tion and no previous anti-VEGF therapy, and was –147 
μm in the group of patients previously treated with laser 
photocoagulation and anti-VEGF injections. This de-
crease was also rapid and a significant benefit on macular 
edema was obtained as early as 1 week after the injection 
of the study drug.
 Although there was a statistically significant increase 
in IOP from baseline to month 12, ILUVIEN ® appeared 
to be safe and well tolerated in all patients of our study. In 
the FAME study, 37.1% of patients had IOP reported as 
an adverse event and 38.4% of patients receiving ILUVI-
EN ® received IOP-lowering medication  [13] . In our 
study, IOP over 22 mm Hg was reported as an adverse 
event in 5 out of 12 patients. The IOP rise was well con-
trolled with topical medication only. Of the 5 patients 
with an elevated IOP, only 2 experienced an IOP over 25 
mm Hg, and none had an IOP over 30 mm Hg.
 Our results are comparable with real-world data from 
Portugal, where other studies  [19–21] have shown a sus-
tained improvement in visual acuity and significant de-
crease in retinal thickness in DME patients with an insuf-
ficient response to prior treatments. The IOP was man-
ageable and may not be considered a problem as long as 
patients are correctly monitored and managed for treat-
ment. The reduced number of patients included in this 
exploratory study is, however, a clear limitation and the 
lack of visual acuity analysis postcataract surgery did not 
allow the full assessment of the visual efficacy of ILUVI-
EN ® .
 In conclusion, in this population with chronic DME a 
rapid and sustained improvement of macular edema was 
obtained after treatment with the ILUVIEN ® intravitreal 
implant. This study showed that patients with chronic 
DME considered insufficiently responsive to available 
therapies experienced improvements in BCVA (+3.7 let-
ters), with a greater BCVA improvement among pseudo-
phakic patients (+6.8 letters) at 12 months after ILUVI-
EN ® injection.
 The decrease in the mean CST from baseline to month 
12 was statistically significant, with a rapid reduction of 
the mean CST in the first week, which is anatomic evi-
dence of the efficacy of the treatment. Regarding safety, 
only 2 patients showed an IOP increase over 25 mm Hg 
during the study, and only eye drops were used to control 
the IOP. This prospective, nonrandomized, multicenter, 
open-label, phase 4 pilot study suggests that ILUVIEN ® 
is safe and may be considered effective for chronic DME 
patients considered insufficiently responsive to available 
therapies.
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